Register below to View Webinar
Disease Modeling in the 21t Century: Automated Organoid Assays with 3D Imaging
Evan F. Cromwell, PhD (President & CEO, Protein Fluidics, Inc.)
Oksana Sirenko, PhD (Senior Research Scientist, Molecular Devices, Inc.)
Date presented: Nov 5, 2020, Thursday
In recent years, researchers have transitioned from traditional 2D assays to more complex 3D cell models, as they are shown to recapitulate the in vivo environment and serve as a more predictive tool for drug discovery. With this transition, there has been an increased need to automate the processing and analysis of 3D cell culture assays for a more simplified, “hands-off” workflow that yields better results.
In this webinar, we present a workflow which integrates the Protein Fluidics’ Pu·MA System for automated organoid assays followed by imaging using ImageXpress® Micro Confocal High-Content Imaging System.
- Automate media exchange, sampling, and staining of complex 3D systems such as spheroids, organoids, and tumoroids
- Acquire quality images at high throughput with water immersion objectives
- Measure and analyze calcium oscillations in neuro-spheroids using the FLIPR® Penta High-Throughput Cellular Screening System
- Perform 3D volumetric analysis and other custom analyses for phenotypic characterization of compound effects
Jul 9, 2020 Protein Fluidics' Organoid Research Award: Prof. Matthew E. Burow & team (Tulane Univ)
Jan 25, 2020 Protein Fluidics launches Pu·MA System 3D for automated organoid assays
December 4, 2018 Protein Fluidics partners with BioLegend to provide Assay Products
May 4, 2018 Protein Fluidics announces the Pu·MA system
October 1, 2016 Protein Fluidics moves into new headquarters in Burlingame, CA
April 6, 2016 Protein Fluidics closes Series seed round of investment
For Research Use Only. Not for diagnostic use. Protein Fluidics, Protein Fluidics Logo and Pu•MA System are registered trademarks of Protein Fluidics, Inc. in the United States and internationally. All rights reserved. © 2021 PROTEIN FLUIDICS, INC.